The FDA approved ribociclib, a CDK4/6 inhibitor, providing an additional treatment option for patients with early breast cancer at high risk for recurrence.

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses. Objective ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

Kisqali (ribociclib), a CDK4/6 inhibitor, has made significant strides in the treatment of HR-positive, HER2-negative early breast cancer, although several follow-up studies are being conducted to ...

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...

Geode Capital Management LLC reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% ...